15226 Federal Register / Vol. 80, No. 55 / Monday, March 23, 2015 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of the following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; New 

Approaches to Synthetic Lethality for Mutant 

KRas-Dependent Cancers (U01). 

Date: April 13, 2015. 

Time: 11:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute Shady 

Grove; 9609 Medical Center Drive; Room 

7W032; Rockville, MD 20850; (Telephone 

Conference Call). 

Contact Person: Clifford W. Schweinfest, 

Ph.D.; Scientific Review Officer; Special 

Review Branch; Division of Extramural 

Activities; National Cancer Institute, NIH; 

9609 Medical Center Drive, Room 7W108; 

Bethesda, MD 20892–9750; 240–276–6343; 

schweinfestcw@mail.nih.gov. 

Name of Committee: National Cancer 

Institute Initial Review Group; Subcommittee 

A—Cancer Centers. 

Date: May 7, 2015. 

Time: 8:00 a.m. to 4:45 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Doubletree Hotel Bethesda; 

(Formerly Holiday Inn Select); 8120 

Wisconsin Avenue; Bethesda, MD 20814. 

Contact Person: Shamala K. Srinivas, 

Ph.D.; Associate Director; Office of Referral, 

Review, and Program Coordination; Division 

of Extramural Activities; National Cancer 

Institute, NIH; 9609 Medical Center Drive, 

7W530; Bethesda, MD 20892–9750; 240–276– 

6442; ss537t@nih.gov. 

Information is also available on the 

Institute’s/Center’s home page: http://

deainfo.nci.nih.gov/advisory/sep/sep.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: March 17, 2015. 

Melanie J. Gray, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2015–06477 Filed 3–20–15; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of Start-up 

Exclusive Evaluation Option License 

Agreement: Pre-Clinical Evaluation 

and Commercial Development of AntiTyrosine Kinase-Like Orphan Receptor 

1 Antibody-Drug Conjugates for the 

Treatment of Human Cancers 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: This is notice, in accordance 

with 35 U.S.C. 209 and 37 CFR part 404, 

that the National Institutes of Health, 

Department of Health and Human 

Services, is contemplating the grant of a 

start-up exclusive evaluation option 

license agreement to practice the 

inventions embodied in U.S. Patent 

Application No. 61/172,099 entitled 

‘‘Anti-human ROR1 Antibodies’’ filed 

April 23, 2009 [HHS Ref. E–097–2009/ 

0–US–01], PCT Application No. PCT/

US2010/032208 entitled ‘‘Anti-human 

ROR1 Antibodies’’ filed April 23, 2010 

[HHS Ref. E–097–2009/0–PCT–02], 

European Patent Application No. 

10715077.3 entitled, ‘‘Anti-human 

ROR1 Antibodies’’ filed October 24, 

2011 [HHS Ref. No. E–097–2009/0–EP– 

03], U.S. Patent Application No. 13/

265,582 entitled, ‘‘Anti-human ROR1 

Antibodies’’ filed October 21, 2011 

[HHS Ref. No. E–097–2009/0–US–04], 

Australian Patent Application No. 

2010238723 entitled, ‘‘Anti-human 

ROR1 Antibodies’’ filed October 21, 

2011 [HHS Ref. No. E–097–2009/0–AU– 

04], Canadian Patent Application No. 

2,759,733 entitled, ‘‘Anti-human ROR1 

Antibodies’’ filed October 21, 2011 

[HHS Ref. No. E–097–2009/0–CA–05], 

US Provisional Application No. 61/

418,550 entitled, ‘‘Chimeric rabbit/

human ROR1 antibodies’’ filed 

December 1, 2010 [HHS Ref. E–039– 

2011/0–US–01], PCT Application No. 

PCT/US2011/062670 entitled, 

‘‘Chimeric rabbit/human ROR1 

antibodies’’ filed November 30, 2011 

[HHS Ref. E–039–2011/0–PCT–02]; 

Australian Patent Application No. 

2011336650 entitled, ‘‘Chimeric rabbit/ 

human ROR1 antibodies’’ filed 

November 30, 2011 [HHS Ref. E–039– 

2011/0–AU–03], Canadian Patent 

Application No. 2818992 entitled, 

‘‘Chimeric rabbit/human ROR1 

antibodies’’ filed November 30, 2011 

[HHS Ref. E–039–2011/0–CA–04], 

European Patent Application No. 

11791733.6 entitled, ‘‘Chimeric rabbit/

human ROR1 antibodies’’ filed 

November 30, 2011 [HHS Ref. E–039– 

2011/0–EP–05] and U.S. Patent 

Application No. 13/990,977 entitled, 

‘‘Chimeric rabbit/human ROR1 

antibodies’’ filed May 31, 2013 [HHS 

Ref. E–039–2011/0–US–06] and all 

related continuing and foreign patents/ 

patent applications for the technology 

family to NBE Therapeutics, Ltd. The 

patent rights in these inventions have 

been assigned to the Government of the 

United States of America. 

The prospective start-up exclusive 

evaluation option license territory may 

be worldwide and the field of use may 

be limited to pre-clinical evaluation and 

commercial development of an 

antibody-drug conjugate comprising an 

anti-tyrosine protein kinase 

transmembrane receptor (ROR1) 

antibody for the treatment of human 

ROR1 expressing cancers utilizing 

enzymatic conjugation methods linking 

a small molecule to a full-length 

antibody, wherein the full-length 

antibody moiety comprises the antiROR1 antibodies or CDR3s within the 

scope of the Licensed Patent Rights. For 

avoidance of doubt, this Agreement 

explicitly excludes the following: (a) 

Antibody-drug conjugates utilizing nonenzymatic conjugation linking small 

molecules to said antibodies, (b) 

immunotoxins comprising anti-ROR1 

antibodies and Pseudomonas exotoxins, 

and (c) non-full-length bispecific 

antibodies. Upon expiration or 

termination of the start-up exclusive 

evaluation option license, NBE 

Therapeutics, Ltd. will have the right to 

execute a start-up exclusive patent 

commercialization license which will 

supersede and replace the start-up 

exclusive evaluation option license with 

no broader territory than granted in the 

start-up exclusive evaluation option 

license and the field of use will be 

commensurate with the commercial 

development plan at the time of 

conversion. 

DATED: Only written comments and/or 

applications for a license which are 

received by the NIH Office of 

Technology Transfer on or before April 

6, 2015 will be considered. 

mstockstill on DSK4VPTVN1PROD with NOTICES